RETRACTED: Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib

Hallaj, Shahin; Asl, Sima Heydarzadeh; Alian, Fatemeh; Farshid, Sajjad; Eshaghi, Farzaneh Sadat; Namdar, Afshin; Atyabi, Fatemeh; Masjedi, Ali; Hallaj, Tooba; Ghorbani, Anahita; Ghalamfarsa, Ghasem; Sojoodi, Mozhdeh; Jadidi‐Niaragh, Farhad

doi:10.1016/j.lfs.2020.118150

Cited by 24 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This approach simultaneously inhibits CD73 and CDKs, effectively controlling tumor progression and metastasis. 113 Furthermore, research involving chitosan-lactic acid-PEG-TAT (CLP-TAT) nanoparticles loaded with siRNA molecules targeting CD73 and IL-6 reported a significant reduction in tumor size, a notable increase in the survival rate of mice carrying tumors (4T1 and CT26 models), and enhanced anti-tumor T lymphocyte responses. 114…”

Section: Nanoparticles Targeting the Adenosine Pathway For Cancer Imm...mentioning

confidence: 99%

Nanoparticles targeting the adenosine pathway for cancer immunotherapy

Jiang,

Wu,

Wang

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Nanoparticles Targeting the Adenosine Pathway For Cancer Imm...mentioning

confidence: 99%

Nanoparticles targeting the adenosine pathway for cancer immunotherapy

Jiang,

Wu,

Wang

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Furthermore, the combination of chemotherapeutic drugs with gene therapy, specifically siRNA co-delivery via nanoparticles, was found to be more successful in the reversal of cancer MDR by targeting cellular signaling pathways [ 81 , 82 ]. Nanocarriers provide stability to siRNA, thereby preventing its rapid degradation and clearance in the cellular system [ 83 ].…”

Section: Nanotechnology-based Strategies To Overcome Mdrmentioning

confidence: 99%

“…For example, Hallaj et al . showed the role of folic acid-conjugated chitosan nanoparticles for co-delivery of anti-CD73 siRNA and dinaciclib to manage tumor growth and to reverse drug resistance in murine breast cancer 4T1 cells, murine colon cancer CT26 cells and in xenograft mice [ 82 ]. Targeting the CDK4/6 cell cycle machinery using palbociclib and hydroxychloroquine-conjugated silica nanoparticles enhanced the biodistribution profile of chemotherapeutics and contributed to the reversal of MDR in pancreatic ductal adenocarcinoma in a xenograft mice model [ 180 ].…”

Section: Recent Advancements In Nanotechnology To Overcome Mdrmentioning

confidence: 99%

Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer

2022

View full text Add to dashboard Cite

Cancer often develops multidrug resistance (MDR) when cancer cells become resistant to numerous structurally and functionally different chemotherapeutic agents. MDR is considered one of the principal reasons for the failure of many forms of clinical chemotherapy. Several factors are involved in the development of MDR including increased expression of efflux transporters, the tumor microenvironment, changes in molecular targets and the activity of cancer stem cells. Recently, researchers have designed and developed a number of small molecule inhibitors and derivatives of natural compounds to overcome various mechanisms of clinical MDR. Unfortunately, most of the chemosensitizing approaches have failed in clinical trials due to non-specific interactions and adverse side effects at pharmacologically effective concentrations. Nanomedicine approaches provide an efficient drug delivery platform to overcome the limitations of conventional chemotherapy and improve therapeutic effectiveness. Multifunctional nanomaterials have been found to facilitate drug delivery by improving bioavailability and pharmacokinetics, enhancing the therapeutic efficacy of chemotherapeutic drugs to overcome MDR. In this review article, we discuss the major factors contributing to MDR and the limitations of existing chemotherapy- and nanocarrier-based drug delivery systems to overcome clinical MDR mechanisms. We critically review recent nanotechnology-based approaches to combat tumor heterogeneity, drug efflux mechanisms, DNA repair and apoptotic machineries to overcome clinical MDR. Recent successful therapies of this nature include liposomal nanoformulations, cRGDY-PEG-Cy5.5-Carbon dots and Cds/ZnS core–shell quantum dots that have been employed for the effective treatment of various cancer sub-types including small cell lung, head and neck and breast cancers. Graphical Abstract

show abstract

“…The currently developed FA-targeted drug delivery systems include various kinds of nanoparticles, e.g., liposomes, micelles, carbon nanotubes, nanorods, core-shell quantum dots, nanospheres, mesoporous nanoparticles and dendrimers (Table 1, Figure 2). The NP have been analysed for achieving an effective antitumour effect by several strategies: single drug delivery [42][43][44][45][46], co-delivery of more than one drug [47][48][49], co-delivery of drug and gene [50][51][52][53], phototherapy [54][55][56], systems combining cancer treatment and diagnosis [57][58][59][60][61] and gene delivery [53,62]. Some drug delivery systems use magnetic ions [63][64][65] or gold nanoparticles [66].…”

Section: Examples Of Folic Acid-targeted Nanoparticlesmentioning

confidence: 99%

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the major causes of death worldwide and its treatment remains very challenging. The effectiveness of cancer therapy significantly depends upon tumour-specific delivery of the drug. Nanoparticle drug delivery systems have been developed to avoid the side effects of the conventional chemotherapy. However, according to the most recent recommendations, future nanomedicine should be focused mainly on active targeting of nanocarriers based on ligand-receptor recognition, which may show better efficacy than passive targeting in human cancer therapy. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumour microenvironment. Thus, the NPs are improved toward an additional functionality, e.g., pH-sensitivity (advanced single-targeted NPs). Moreover, dual-targeted nanoparticles which contain two different types of targeting agents on the same drug delivery system are developed. The advanced single-targeted NPs and dual-targeted nanocarriers present superior properties related to cell selectivity, cellular uptake and cytotoxicity toward cancer cells than conventional drug, non-targeted systems and single-targeted systems without additional functionality. Folic acid and biotin are used as targeting ligands for cancer chemotherapy, since they are available, inexpensive, nontoxic, nonimmunogenic and easy to modify. These ligands are used in both, single- and dual-targeted systems although the latter are still a novel approach. This review presents the recent achievements in the development of single- or dual-targeted nanoparticles for anticancer drug delivery.

show abstract

RETRACTED: Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib

Cited by 24 publications

References 43 publications

Nanoparticles targeting the adenosine pathway for cancer immunotherapy

Nanoparticles targeting the adenosine pathway for cancer immunotherapy

Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

Contact Info

Product

Resources

About